1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Investigación quirúrgica en urología y trasplante renal

Investigación quirúrgica en urología y trasplante renal

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Parente A, Verhoeff K, Wang Y, Wang N, Wang Z, Sledzinski M, Hellmann A, Raffaelli M, Pennestrì F, Sywak M, Papachristos AJ, Palazzo FF, Sung TY, Kim BC, Lee YM, Eatock F, Anderson H, Iacobone M, Daukša A, Makay O, Turk Y, Basut Atalay H, Nieveen van Dijkum EJM, Engelsman AF, Holscher I, Materazzi G, Rossi L, Becucci C, Shore SL, Fung C, Waghorn A, Mihai R, Balasubramanian SP, Pannu A, Tatarano S, Velázquez-Fernández D, Miller JA, Serrao-Brown H, Chen Y, Demarchi MS, Djafarrian R, Doran H, Wang K, Stechman MJ, Perry H, Hubbard J, Lamas C, Mercer P, MacPherson J, Lumbiganon S, Calatayud M, Alexandra Hanzu F, Vidal O, Araujo-Castro M, Minguez Ojeda C, Papavramidis T, Rodríguez de Vera Gómez P, Aldrees A, Altwjry T, Valdés N, Álvarez-Escola C, García Sanz I, Blanco Carrera C, Manjón-Miguélez L, De Miguel Novoa P, Recasens M, García Centeno R, Robles Lázaro C, Van Den Heede K, Van Slycke S, Michalopoulou T, Aspinall S, Melvin R, Lau JWL, Cheah WK, Tang MH, Oh HB, Ayuk J, Sutcliffe RP.

    Robotic and Laparoscopic Adrenalectomy for Pheochromocytoma An International Multicenter Study

    European Urology Focus . 11(1): 118-125. Nº de citas: 9

    [doi:10.1016/j.euf.2024.09.001]

  • Santoni M, Roviello G, Grande E, De Giorgi U, Fiala O, Seront E, Molina-Cerrillo J, Pichler R, Myint ZW, Kucharz J, Kanesvaran R, Büttner T, Pichler M, Basso U, Kopecky J, Bourlon MT, Cerbone L, Buchler T, Pinto A, de Liaño AG, Gianni C, Zgura A, Rescigno P, Ansari J, Caffo O, Küronya Z, Vitale MG, Bhuva D, Catalano M, Vau N, Kopp RM, Buti S, Bamias A, Porta C, Sunela K, Massari F.

    Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 74(7): 225-225. Nº de citas: 6

    [doi:10.1007/s00262-025-04043-x]

  • Gómez Rivas J, de la Parra I, Infante S, Ibañez L, Gutierrez Hidalgo B, Cabrera MN, Puente J, Sanmamed N, Ortega Polledo LE, Galante MI, Moreno Sierra J.

    Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era.

    Medicina-Lithuania . 61(5): . Nº de citas: 1

    [doi:10.3390/medicina61050924]

  • Scilipoti P, Longoni M, de Angelis M, Zaurito P, Slusarczyk A, Soria F, Pradere B, Krajewski W, D'Andrea D, Mari A, Giudice FD, Pichler R, Subiela JD, Marcq G, Gallioli A, Afferi L, Mastroianni R, Simone G, Albisinni S, Mertens LS, Laukhtina E, Oberneder K, Rodríguez Elena JL, Aranda J, Puentedura AL, Velasco JC, Contieri R, Hurle R, Mori K, Radziszewski P, Shariat SF, Gontero P, Necchi A, Rouprêt M, Montorsi F, Salonia A, Briganti A, Moschini M.

    Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin (BCG): A Comparative Analysis of Adequate Versus Inadequate BCG Treatment.

    European Urology Focus . 12(1): 70-78. Nº de citas: 15

    [doi:10.1016/j.euf.2025.04.033]

  • Porta C, Massari F, Taha T, Grande E, Bourlon MT, Kanesvaran R, Basso U, Molina-Cerrillo J, Alonso-Gordoa T, Myint ZW, Fornarini G, Buttner T, Park SH, Ürün Y, De Giorgi U, Pichler R, Rescigno P, Buchler T, Studentova H, Melichar B, Ansari J, Mollica V, Kucharz J, Rizzo M, Rizzo A, Kopp RM, Buti S, Monteiro FSM, Soares A, Bamias A, Santoni M.

    Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON-1 study

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 74(7): 196-196. Nº de citas: 10

    [doi:10.1007/s00262-025-04019-x]

  • Alonso-Gordoa T, Anguera G, Domínguez-Esteban M, Reig Ò, Martínez-Barros H, Molina-Cerrillo J, Cruz P, Maroto P.

    Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies.

    CANCER TREATMENT REVIEWS . 136: 102925-102925. Nº de citas: 3

    [doi:10.1016/j.ctrv.2025.102925]

  • Artero Fullana S, Caño Velasco J, Lafuente Puentedura A, Polanco Pujol L, Bataller Monfort V, Moralejo Gárate M, Subiela JD, Gallioli A, Moschini M, Pichler R, Del Giudice F, Marcq G, Teoh J, Soria F, Mertens L, Krajewski W, Laukhtina E, Mori K, Pradere B, Afferi L, Tully KH, Albisinni S, Abu Ghanem Y, d'Andrea D, Mari A, Albers Acosta E, Contieri R, Cimadamore A, Grobet-Jeandin E, Gómez Rivas J, Hernández Fernández C.

    Diagnostic accuracy of Bladder EpiCheck for upper tract urothelial carcinoma: A meta-analysis.

    Actas Urologicas Espanolas . 49(4): 501720-501720.

    [doi:10.1016/j.acuroe.2025.501720]

  • Gallioli A, Uleri A, Verri P, Tedde A, Mertens LS, Moschini M, Del Giudice F, Soria F, Laukhtina E, Subiela JD, Krajewski W, D'Andrea D, Mari A, Marcq G, Mori K, Teoh J, Afferi L, Albisinni S, Sanguedolce F, Palou J, Breda A, Pradere B.

    Oncologic Outcomes of Endoscopic Management of Upper Tract Urothelial Carcinoma: A Systematic Review and Pooled Analysis from the EAU-YAU Urothelial Working Group

    European Urology Focus . 11(3): 482-495. Nº de citas: 4

    [doi:10.1016/j.euf.2025.01.009]

  • Rivero Belenchón I, Congregado Ruíz CB, Gómez Ciriza G, Gómez Dos Santos V, Burgos Revilla FJ, Medina López RA.

    Impact of 3D-Printed Models for Surgical Planning in Renal Cell Carcinoma With Venous Tumor Thrombus: A Randomized Multicenter Clinical Trial.

    JOURNAL OF UROLOGY . 213(5): 568-580. Nº de citas: 13

    [doi:10.1097/JU.0000000000004425]

  • Laszkiewicz J, Del Giudice F, Li S, Krajewski W, Nowak L, Szydelko T, Basran S, De Berardinis E, Carino D, Corvino R, Santerelli V, Ferro M, Rocco B, Sighinolfi MC, Crocetto F, Barone B, Dinacci F, Pichler R, Subiela JD, Pradere B, Moschini M, Mari A, Gallioli A, Mori K, Soria F, Mertens L, Abu-Ghanem Y, Nair R, Khan MS, Chung BI.

    Novel risk factors for venous thromboembolism following outpatient or inpatient transurethral resection of bladder tumors: Multivariable stepwise and LASSO regression modeling from us insurance claim database.

    Actas Urologicas Espanolas . 49(4): 501738-501738. Nº de citas: 2

    [doi:10.1016/j.acuroe.2025.501738]

  • Rodríguez-Moreno JF, de Velasco G, Álvarez-Fernández C, Collado R, Fernández R, Vázquez S, Virizuela JA, Gajate P, Font A, Lainez N, Sevillano-Fernández E, Graña-Castro O, Beltrán L, Madurga R, Rodríguez-Antona C, Berraondo P, Ruiz-Llorente S, García-Donas J.

    Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial

    CLINICAL CANCER RESEARCH . 31(9): 1644-1656. Nº de citas: 1

    [doi:10.1158/1078-0432.CCR-24-2890]

  • Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Viñuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-García M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taïeb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Álvarez-Álvarez R, Lousberg L, Aboubakar Nana F, Hernando J, García-Álvarez A, García-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A.

    A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

    BMC CANCER . 25(1): 613-613. Nº de citas: 9

    [doi:10.1186/s12885-025-13941-3]

  • Basile G, Uleri A, Leni R, Cannoletta D, Afferi L, Baboudjian M, Diana P, D'Andrea D, Teoh J, Pradere B, Subiela JD, Laukhtina E, Seisen T, Rouprêt M, Briganti A, Montorsi F, Moschini M, Breda A, Gallioli A.

    En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis of Oncological Histopathological, and Surgical Outcomes

    European Urology Oncology . 8(2): 520-533. Nº de citas: 14

    [doi:10.1016/j.euo.2024.10.004]

  • Gómez Del Val A, Sánchez A, Freire-Agulleiro Ó, Martínez MP, Muñoz M, Olmos L, Medina JS, Comerma-Steffensen SG, Simonsen U, Rivera L, López M, Contreras C, Prieto D.

    Penile endothelial dysfunction, impaired redox metabolism and blunted mitochondrial bioenergetics in diet-induced obesity: Compensatory role of H(2)O(2).

    FREE RADICAL BIOLOGY AND MEDICINE . 230: 222-233. Nº de citas: 11

    [doi:10.1016/j.freeradbiomed.2025.02.004]

  • Pal SK, Powles T, Kanesvaran R, Molina-Cerrillo J, Feldman DR, Barata P, Liu M, Bhatt A, Wang Z, Nandoskar P, Suarez C.

    STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma

    Future Oncology . 21(7): 787-794. Nº de citas: 3

    [doi:10.1080/14796694.2025.2458395]

  • Del Olmo-García M, Hernandez-Rienda L, Garcia-Carbonero R, Hernando J, Custodio A, Anton-Pascual B, Gomez M, Palma Milla S, Suarez L, Bellver M, Alonso V, Serrano R, Valdés N, Melian M, Febrero B, Sampedro-Nuñez MA, Biarnes J, Díaz-Pérez JÁ, Molina-Cerrillo J, Lopez C, Martínez Olmos MÁ, Merino-Torres JF, Capdevila J, Argente Pla M.

    Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study

    ONCOLOGIST . 30(2): . Nº de citas: 8

    [doi:10.1093/oncolo/oyae343]

  • Rizzo M, Morelli F, Ürün Y, Buti S, Park SH, Bourlon MT, Grande E, Massari F, Landmesser J, Poprach A, Takeshita H, Roviello G, Myint ZW, Popovic L, Soares A, Abahssain H, Giannatempo P, Molina-Cerrillo J, Incorvaia L, Salah S, Zeppellini A, Monteiro FSM, Porta C, Gupta S, Santoni M.

    Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

    Cancer Medicine . 14(4): . Nº de citas: 9

    [doi:10.1002/cam4.70479]

  • Fiala O, Buti S, Fujita K, de Liaño AG, Fukuokaya W, Kimura T, Yanagisawa T, Giannatempo P, Angel M, Mennitto A, Molina-Cerrillo J, Bourlon MT, Soares A, Takeshita H, Calabrò F, Ortega C, Kucharz J, Milella M, Seront E, Park SH, Tural D, Benedetti G, Ürün Y, Battelli N, Melichar B, Poprach A, Buchler T, Kopecký J, Conteduca V, Monteiro FSM, Massari F, Gupta S, Santoni M.

    Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study

    CLINICAL & EXPERIMENTAL METASTASIS . 42(2): 18-18. Nº de citas: 3

    [doi:10.1007/s10585-025-10335-4]